April 2, 2022- ARTICLE

Lansky A, White J, Stewart J, et al. CLINICAL PREDICTORS OF EMBOLIC BURDEN AFTER TAVR: AN ANALYSIS OF THE SAFEPASS 2 CLINICAL STUDY. J Am Coll Cardiol. 2022 Mar, 79 (9_Supplement) 628.

May 25, 2021- PRESS RELEASE

Emboline Raises over $55 Million in Series D Funding for Pivotal FDA Clinical Study and Market Launch of the Emboliner® Embolic Protection Catheter to Minimize Stroke Risk from TAVR

January 5, 2021- PRESS RELEASE

Emboline™ Raises Over $10 Million in Series C Funding to Fund Further Development of the Emboliner™ Embolic Protection Catheter to Minimize Stroke Risk From TAVR

October 14, 2020- ABSTRACT

Clinical Performance of a Total Embolic Protection Device: Results of the Emboliner SafePass 2 Study. Sanjeevan Pasupati MD, Waikato Hospital, Hamilton, New Zealand. TCT 2020.

Emboline, Inc.
Santa Cruz, CA USA
Tel: +1 (831) 900-5020 • Fax: +1 (831) 900-5019